不同的疾病,不同的需求:在溶酶体储存障碍中,患者对基因治疗的偏好,概率值技术调查
Eleonore M Corazolla1,2,3, Eline C B Eskes1,3, Jorien Veldwijk4,5
1Department of Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
Orphanet journal of rare diseases
|October 4, 2024
概括
患者对基因疗法的风险耐受性因 lysosomal 储存疾病的严重程度而异. 预后较差,治疗选择较少的人对新型基因疗法具有更高的风险耐受性.
科学领域:
- 遗传学和基因组学 在
- 医学遗传学 医学遗传学
- 罕见疾病 罕见疾病
背景情况:
- 基因疗法是一种正在发展中的单基因疾病治疗方法,包括溶酶体储存障碍 (LSD).
- 有限的数据存在于LSD群体的患者偏好和基因治疗的风险耐受性.
- 这项研究调查了不同LSD的风险耐受性,其预后和治疗可用性各不相同.
研究的目的:
- 为了在患有高氏病,法布里病和III型粘多糖症 (MPS III) 的患者中比较基因治疗相关的风险耐受性.
- 了解疾病的严重程度和当前的治疗选择如何影响患者对基因治疗的偏好.
主要方法:
- 使用概率值技术进行了一项调查,以评估风险容忍度.
- 参与者在基因治疗和标准护理之间做出选择,考虑诸如副作用风险,需要药物治疗和长期有效性等属性.
- 调查受访者包括Gaucher病 (1型) 患者,Fabry病患者和MPS III (A/B) 患者的父母.
主要成果:
- 较高的疾病严重程度与较高的风险耐受性相关;MPS III代表比Gaucher病受访者更能耐受风险.
- 弗里病患者表现出异质的风险耐受性,男性比女性更耐受.
- 在所有参与者群体中,长期有效性是最不被容忍的属性.
结论:
- 患者对基因疗法的风险耐受性受到疾病预后和当前治疗的疗效的影响.
- 在基因疗法开发的早期纳入患者偏好对于罕见疾病至关重要,以确保与患者的需求和期望保持一致.
关键词:
费布里病是什么意思 费布里病是什么意思戈舍氏病1型1型的疾病.基因治疗是一种基因疗法.lysosomal 储存疾病 lysosomal 储存疾病粘多糖症 III 型 A/B 型患者的偏好 患者的偏好概率学值技术的使用.更多相关视频
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
10.9K
05:09Lumbar Intrathecal Injection of Gene Therapy Vectors for Central Nervous System Targeting in Mice and Rats
Published on: May 16, 2025
250
相关概念视频
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
00:59Gene Therapy
25.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.3K